Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Overview
Date Founded

2007

Headquarters

88 Sidney Street,Cambridge, MA 02139-4169

Type of Company

Public

Employees (Worldwide)

536

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Agios Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Founder

Chief Executive Officer & Director

Chief Financial Officer & Head of Corporate Development

Chief Scientific Officer

Chief Legal Officer

Chief People Officer

Chief Medical Officer

Board of Directors

General Partner at GV Management Co. LLC

Chief Executive Officer & Director at Agios Pharmaceuticals, Inc.

Senior Advisor at The Boston Consulting Group, Inc.

Former Executive Vice President & Chief Financial Officer at Alexion Pharmaceuticals, Inc.

Co-Founder at Fate Therapeutics, Inc.

Chief Executive Officer, Director at Alnylam Pharmaceuticals, Inc.

Healthcare Venture Partner at Qiming Venture Partners Ltd.

Operating Partner at Clarus Ventures LLC

Paths to Agios Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Agios Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

Founded in 2007, ArrowMark Partners is an SEC-registered investment adviser headquartered in Denver, CO and adviser to the Meridian Funds family. The founding partners have worked together since 1995.

Recent Transactions
Details Hidden

Agios Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Agios Pharmaceuticals, Inc. issued . USD Common Stock

Details Hidden

Agios Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onAgios Pharmaceuticals, Inc. issued . USD Common Stock

Legal Advisor

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Assurance Partner at Ernst & Young LLP

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. It offers cancer therapeutics with a special focus on immuno-oncology based combination therapies. The company was founded on December 2, 2015 and is headquartered in Shanghai, China.

Key Stats and Financials As of 2019
Market Capitalization
$3.61B
Total Enterprise Value
$2.41B
Earnings Per Share
$-6.86
Revenue
$118M
Net Profit
$-411M
EBITDA
$-410M
EBITDAMargin
-347.47%
Total Debt
$114M
Total Equity
$641M
Enterprise Value Sales
20.47x
TEVNet Income
-5.87x
Debt TEV
0.05x
Five Year Compounded Annual Growth Rate Of Revenue
12.53%
Three Year Compounded Annual Growth Rate Of Revenue
19.04%
Non-Profit Donations & Grants
Investors
Details Hidden

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

Flagship Pioneering focuses on investments in the following sectors: (1) therapeutics (2) life science tools and diagnostics and (3) bioenergy and clean technology. The firm looks for companies with exceptional management teams and significant commercial opportunities resulting from market discontinuities or technology breakthroughs. Flagship Ventures typically serves as lead investor. The majority of their investments are seed or first round investments. Initial investments range from $250,000 to $5 million, with typically initial investments ranging from $2.5 million to $4 million. Flagship Ventures may invest up to $15 million to $20 million over the life of a venture and typically forms syndicates that include other venture capital firms

Suppliers
Foundation Medicine, Inc. Medical Support Services | Cambridge, MA

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded by Alexis Borisy in November 2009 and is headquartered in Wilmington, DE.

Forest City Realty Trust, Inc. Trusts & Funds | Cleveland, OH

Forest City Realty Trust, Inc. engages in the provision of real estate investment. Its activities include ownership, development, management, and acquisition of commercial and residential real estate throughout the United States. The company's project portfolio consists of apartment properties, build-to-suit buildings, and regional and urban retail centers. Forest City Realty Trust was founded by Charles Ratner, Max, Ratner, Leonard Ratner and Fannye Ratner in 1920 and is headquartered in Cleveland, OH.

Dr Reddy's Laboratories Ltd. Medical Support Services | Hyderabad, India

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Awards & Honors
2014
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Agios Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Agios Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Agios Pharmaceuticals, Inc..